Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race

All NewsApril 17, 2026

Kailera Therapeutics prices $625 million IPO, advances GLP-1 obesity pipeline as trial data highlights oral ribupatide weight loss results.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent